ReviewCerebellum (London, England)2004
Progressive myoclonic epilepsy.
Review in Cerebellum (London, England), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis.Orphanet journal of rare diseases · 2021Pooled it
- The cerebellum in epilepsy.Epilepsia · 2025Review
- Exploring individual fixel-based white matter abnormalities in epilepsy.Brain communications · 2024Article
- The involvement of Purkinje cells in progressive myoclonic epilepsy: Focus on neuronal ceroid lipofuscinosis.Neurobiology of disease · 2023Review
- Non-convulsive Status Epilepticus inFrontiers in pediatrics · 2022Article
- Adult-onset rapidly worsening progressive myoclonic epilepsy caused by a novel variant in DHDDS.Annals of clinical and translational neurology · 2021Article
- Lafora body disease: a case of progressive myoclonic epilepsy.BMJ case reports · 2020Article
- Neuroinflammation and progressive myoclonus epilepsies: from basic science to therapeutic opportunities.Expert reviews in molecular medicine · 2020Review
- Oxidative Stress, a Crossroad Between Rare Diseases and Neurodegeneration.Antioxidants (Basel, Switzerland) · 2020Review
- Review
- Are There Neurological Symptoms in Type 1 of Gaucher Disease?Iranian journal of child neurology · 2018Article
- Reduced ceramide synthase 2 activity causes progressive myoclonic epilepsy.Annals of clinical and translational neurology · 2014Article
- Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels.Molecular genetics and metabolism · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive myoclonic epilepsies (PMEs) are a group of rare disorders characterized by the occurrence of seizures, myoclonus, and progressive neurological dysfunction. This article discusses epidemiology, genetics, pathology, clinical manifestations, EEG characteristics, methods of diagnosis and treatment of the most common causes of PME, including Unverricht-Lundborg Disease (Baltic Myoclonus), MERRF, neuronal ceroid lipofuscinosis, dentatorubropallidoluysan atrophy, Gaucher disease, Lafora disease, and sialidosis. The aim of this paper is to provide clinicians with useful clinical information in order to facilitate the diagnosis and treatment of these rare diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.